Birmingham-based UAB spinoff will develop treatments for cardio-pulmonary diseases

Clinician and pulmonary biologist Charitharth Vivek Lal, M.D., FAAP of University of Alabama at Birmingham has founded ResBiotech: a platform company and Innovation Institute for cardio-respiratory and maternal-child health technologies. 

ResBiotic is the first Resbiotech company, with two proprietary formulations of the anti-inflammatory probiotic developed by Lal’s Pulmonary Microbiome Lab at UAB currently on the path to market.

This latest feature from UAB News details the roots of our innovation and the resources of our parent company, Resbiotech.

Published by ResBiotic

After years of research, we can now modulate how the microbiota influence lung diseases. The commercialization of this work from University of Alabama at Birmingham, led by ResBiotic founder and Chief Scientific Officer C. Vivek Lal MD FAAP, has the potential to be life changing for respiratory disease patients. ResBiotic is developing first-in-class products that alleviate the neutrophilic inflammation associated with dysbiosis to improve respiratory health.

November 18, 2020

Read Next


Submit a Comment

Your email address will not be published. Required fields are marked *